Vascular Biogenics reported -9434000 in Pre-Tax Profit for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Pre Tax Profit Change
Bluebird Bio BLUE:US $ -100.14M 22.01M
Capricor Therapeutics CAPR:US $ -7.11M 0.71M
Eleven Biotherapeutics EBIO:US $ -0.81M 9.75M
Epizyme EPZM:US $ -35.74M 19.73M
Infinity Pharmaceuticals INFI:US $ -11.99M 0.45M
Newlink Genetics NLNK:US $ -7.84M 0.12M
Prothena PRTA:US $ -42.57M 4.61M
Vascular Biogenics VBLT:US -9434000 994K